BioLife Solutions (BLFS) Gets a Buy from Northland Securities

Northland Securities analyst Carl Byrnes maintained a Buy rating on BioLife Solutions today and set a price target of $34.00.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Byrnes is an analyst with an average return of -4.3% and a 36.95% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as MiMedx Group, BioLife Solutions, and Indivior.

In a report released on December 29, Maxim Group also maintained a Buy rating on the stock with a $34.00 price target.

Based on BioLife Solutions’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $28.07 million and a net profit of $621 thousand. In comparison, last year the company earned a revenue of $30.57 million and had a GAAP net loss of $1.7 million

Based on the recent corporate insider activity of 112 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BLFS in relation to earlier this year. Last month, Amy DuRoss, a Director at BLFS sold 2,000.00 shares for a total of $49,200.00.